Vasculitis & polymyalgia rheumatica
Key considerations for modelling the long-term costs and benefits of treatments for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Authors' conclusion
Economic evaluation of new treatments for AAV needs to capture all relevant downstream effects. ESRD is a key driver of cost-effectiveness but is associated with major uncertainty.
Study context
- Population
- Economic evaluation of new treatments for AAV, using the appraisal of avacopan in England (NICE) as a case study
- Outcome
- A set of recommendations for modelling the cost-effectiveness of new treatments for AAV from the HTA perspective
Methodological detailscase study of the NICE appraisal of avacopan in England, health technology assessment (HTA) perspective
- Case study of the NICE appraisal of avacopan in England
- HTA perspective
Main finding
As reported in the abstract
- Appropriate model structure
- Approach to modelling end-stage renal disease (ESRD) as a key determinant of cost-effectiveness
- Capturing the impact of GC-related adverse events
- Estimation of short and long-term costs of AAV
Original publication
Key considerations for modelling the long-term costs and benefits of treatments for ANCA-associated vasculitis. Clin Exp Rheumatol. Published 18 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →